Provided by Tiger Trade Technology Pte. Ltd.

REVVITY INC

153.60
+0.30000.20%
Post-market: 153.600.00000.00%17:05 EDT
Volume:2.23M
Turnover:342.91M
Market Cap:17.17B
PE:73.35
High:156.01
Open:153.03
Low:149.25
Close:153.30
52wk High:166.25
52wk Low:81.22
Shares:111.80M
Float Shares:102.00M
Volume Ratio:0.90
T/O Rate:2.19%
Dividend:0.28
Dividend Rate:0.18%
EPS(TTM):2.09
EPS(LYR):2.07
ROE:3.21%
ROA:2.37%
PB:2.38
PE(LYR):74.25

Loading ...

Revvity CFO Maxwell Krakowiak Sells 1,631 Shares Worth $235,525.43

Reuters
·
Sep 24

CFRA downgrades Revvity (RVTY) to a Hold

TIPRANKS
·
Sep 21

Weekly Winners | RVTY, CRWD Soar 15%; GNRC, COIN Up Over 10%; PANW, SNDK, FDS Rise More Than 9%

Tiger Newspress
·
Sep 20

S&P 500 Posts Slight Weekly Decline as Utilities Weigh

MT Newswires Live
·
Sep 19

Revvity SVP Global Operations Tajinder S. Vohra Sells 7,330 Shares Worth $1,032,650.40

Reuters
·
Sep 19

Revvity Inc. Stock Climbs 4.0%, Outperforms Peers

Dow Jones
·
Sep 17

Movement Alert|REVVITY INC Rises 5.21% in Regular Trading, Acquisition of Human Cell Design Continues to Boost Market Sentiment

Market Focus
·
Sep 16

Revvity Inc. Stock Climbs 9.1%, Outperforms Peers

Dow Jones
·
Sep 16

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Sep 16

Movement Alert|REVVITY INC Rises 6.11% in Regular Trading, Acquisition of Human Cell Design Bolsters Metabolic Disease R&D Capabilities

Market Focus
·
Sep 15

Revvity Inc. Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 11

Revvity Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 10

UBS Downgrades Revvity to Neutral From Buy, Adjusts Price Target to $140 From $120

MT Newswires Live
·
Sep 09

Revvity (RVTY) Receives a New Rating from UBS

TIPRANKS
·
Sep 09

Revvity to acquire Human Cell Design

TIPRANKS
·
Sep 09

Revvity Agrees to Acquire Human Cell Design in Metabolic Disease Research Push

Reuters
·
Sep 09

Revvity, - Acquisition Adds Hcd's Human Pancreatic Beta Cell Models to Revvity Portfolio

THOMSON REUTERS
·
Sep 09

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

THOMSON REUTERS
·
Sep 09

Revvity, Inc.: Additional Terms of Transaction were not Disclosed

THOMSON REUTERS
·
Sep 09

Revvity Price Target Raised to $165.00/Share from $125.00 by Keybanc

Dow Jones
·
Sep 04